Korea Institute of Science and Technology

The Catholic University of Korea Industry-academic Cooperation Foundation

Korea University Industrial Academic Collaboration Foundation

The Catholic University of Korea Industry-academic Cooperation Foundation, Catholic Univ. of Korea Songeui Campus

The Catholic University of Korea Industry-academic Corporation Foundation

The Catholic University of Korea Industry-academic

Dong-Yun Shin

Mi-La Cho

Min-Jung Park

Seon-Yeong Lee

Sung-Hee Lee

Hye-Jin Son

Jae-Kyung Kim

Chul-Woo Yang

Hoh-Gyu Hahn

Kee-Dal Nam

Eun-Kyung Kim

Sung-Hwan Park

Jong-Young Choi

Eun-Ji Yang

Hye-Whon Rhim

Chi-Man Song

Eun Kyung Kim

Sang-Hoon Lee

Young-Soo Kim

Dong-Jin Kim

Chan-Ho Park

Sung-Woo Cho

Kye-Jung Shin

Eunice Eun-Kyeong Kim

Eun-Jung Lee

Key-Sun Kim

Hyeon-Beom Seo

Joo-Yeon Jhun

Hee-Sup Shin

Seon-Hee Seo

Seung-Hun Lee

Sun-Joon Min

Gyo-Chang Keum

Soon-Bang Kang

Ae-Nim Pae

Eun Ji Yang

Jae-yoon Ryu

Eun-Joo Roh

Keun-Hyung Cho

Eun-A Kim

Cheol-Ju Lee

He-Sson Chung

Se-Young Kim

Woong-Seo Park

Yong-Koo Kang

Chan-Seong Cheong

Seong-Hyeok Park

Min-soo Han

Young-Hue Han

Ghil-Soo Nam

Kyung-Il Chol

Hye-Jin Chung

Hyun-Ah Choo

Yong-Seo Cho

Kee-Hyun Choi

Jae-Kyun Lee

Chul- Woo Yang

Min-Soo Han

The present invention relates to a composition for preventing or treating transplantation rejection or a transplantation rejection disease, comprising a novel compound and a calcineurin inhibitor. A co-administration of the present invention 1) reduces the activity of pathogenic Th1 cells or Th17 cells, 2) increases the activity of Treg cells, 3) has an inhibitory effect against side effects, such as tissue damage, occurring in the sole administration thereof, 4) inhibits various pathogenic pathways, 5) inhibits the cell death of inflammatory cells, and 6) increases the activity of mitochondria, in an in vivo or in vitro allogenic model, a transplantation rejection disease model, a skin transplantation model, and a liver-transplanted patient, and thus inhibits transplantation rejection along with mitigating side effects possibly occurring in the administration of a conventional immunosuppressant alone. Thus, the present invention may be used in the field of pharmaceutics relating to transplantation rejection or various immune disorders possibly occurring after transplantation.

Composition for preventing and treating transplant rejection or transplant rejection diseases, comprising novel compound and calcineurin inhibitor

The present invention relates to a biguanide derivative compound capable of effectively preventing and treating immune diseases. The biguanide-based derivative compound according to the present invention inhibits the generation of IL-17 and TNF-&#x3b1;, which are inflammatory cytokines, increases the activity of regulatory T cells having an immunomodulatory function, and exhibits excellent therapeutic effects in animal models of immune diseases. Accordingly, the biguanide-based derivative compound can be usefully used as an immunosuppressant or a pharmaceutical composition capable of preventing or treating various immune diseases, such as autoimmune diseases, inflammatory diseases, and transplant rejection, caused by the dysregulation of immune responses.

Pharmaceutical composition for preventing or treating immune diseases or inflammatory diseases, containing biguanide derivative compound as active ingredient

Provided is a novel compound capable of effectively preventing and treating immune diseases and a use thereof. The novel compound of the present subject matter has effects of inhibiting the production of inflammatory cytokines, increasing the activity of regulatory T cells having immunoregulatory functions, inhibiting the production of auto-antibodies to regulate excessive immune responses, and inhibiting the differentiation of osteoclasts, and thus can be used for treating immune diseases, such as autoimmune disease, inflammatory disease, and transplant rejection diseases, which are caused by abnormal regulation of various kinds of immune response.

Compound having immune disease treatment effect and use thereof

The daurinol compound according to the present invention exhibits excellent therapeutic effects on arthritis and inflammatory bowel diseases by having an excellent activity in inhibiting the generation of IL-17 and TNF-&#x3b1;, which are inflammatory cytokines causing inflammation, and can alleviate transplant rejection by inhibiting the proliferation of alloreactive T cells and increasing regulatory T cells; therefore, the daurinol compound according to the present invention can be used as a pharmaceutical composition capable of treating and preventing immune diseases. In addition, being a natural substance derived from the Mongolian medicinal plantor, the daurinol compound according to the present invention does not cause cytotoxicity and thus may be used as a composition for a functional health food capable of preventing and remedying immune diseases.

Composition for treating immune diseases containing daurinol compound as active ingredient

The present invention relates to an azetidine derivative or a pharmaceutically acceptable salt thereof, and an antidepressant agent or a composition for the prevention or treatment of psychiatric disorders including the same. The azetidine derivative is useful as a triple reuptake inhibitor capable of inhibiting reuptake of the neurotransmitters, dopamine, serotonin, and norepinephrine at the same time.

Azetidine derivative and antidepressant composition including the same

Novel benzoarylureido compounds and a use thereof for prevention and/or treatment of the neurodegenerative brain disease are provided. The neurodegenerative brain diseases may include Alzheimer's disease, dementia, Parkinson's disease, stroke, amyloidosis, Pick's disease, Lou Gehrig's disease, Huntington's disease, Creutzfeld-Jakob disease, and the like.

Benzoarylureido compounds, and composition for prevention or treatment of neurodegenerative brain disease containing the same

The present invention relates to novel thiazole-based compounds and T-type calcium channel inhibitors containing the compound. The T-type calcium channel inhibitor of the present invention is useful as a treating agent for disease associated with overexpression of T-type calcium channel.

Thiazole-based compound and inhibitor of T-type calcium channel containing the same

Novel 2-imino-1,3-thiazoline based compounds represented by Chemical Formula I, and T-type calcium channel inhibitors containing the compound are provided. The T-type calcium channel inhibitors according to the present invention are useful as a treating agent of diseases associated with over-expression of the T-type calcium channel. 

2-Imino-1,3-thiazoline-based compounds and T-type calcium channel inhibitors containing the same

Disclosed is a memory device using a multi-domain state of a semiconductor material, and more particularly to a magnetic memory device, in which a ferromagnetic layer for recording magnetic data serves as a sensing layer so as to have a simple structure, shorten a manufacturing process, and reduce the unit cost of production. The planar hall effect or magneto-resistance is used to measure multi-domain states so as to read data stored in a multi-level state.

Magnetic memory device using domain structure and multi-state of ferromagnetic material

Growing community of inventors

Seoul, South Korea

Dong-Yun Shin